INTRODUCTION
Streptococcus pneumoniae is a major cause of morbidity and mortality in India, especially in children, the elderly and immunocompromised individuals of all age groups. Penicillin has been an effective and affordable antibiotic for the treatment of invasive pneumococcal disease (IPD). Notably, among the Asian countries, India had the lowest percentage of penicillin intermediate resistance to S. pneumoniae (PIRSP) and virtually no complete penicillin resistance in IPD isolates. [1] [2] [3] Here,
CASE REPORT
we report with great concern, the emergence of penicillin resistant S. pneumoniae (PRSP) in India.
A 26-year-old male presented with recent history of fever, headache, left-side earache and altered sensorium. On examination, signs of meningeal irritation with bilateral sixth nerve palsy were observed. ENT examination revealed acute otitis media. Cerebrospinal ß uid (CSF) indices were suggestive of acute pyogenic meningitis with total CSF leukocyte counts of 2400 /µl (70% PMN), glucose 30 mg/dl and protein 240 mg/dl. The CSF Gram stain and culture were negative, but positive by immuno chromatographic test (ICT), S. pneumoniae Binax ® NOW™. Contrast enhanced CT of the brain did not show any focal lesions. The patient was treated with high dose crystalline penicillin. His blood culture subsequently grew S. pneumoniae, which was found resistant to oxacillin by the disc diffusion test. The penicillin minimum inhibitory concentration (MIC) was 2 µg/ml by broth dilution method. He was treated with intravenous ceftriaxone and vancomycin for a total duration of ten days. His condition improved dramatically and he became afebrile. He was asymptomatic at discharge. Eight months later he developed meningitis again and the CSF grew S. pneumoniae. ENT examination revealed a congenital anomaly for which he subsequently underwent surgery.
The resistant blood isolate from patients with meningeal symptoms and antigen positive is considered a meningitis isolate for MIC interpretation and treatment as per the standard recommended practice. This isolate was characterized at the Centers for Disease Control and Prevention (CDC, Streptococcus Laboratory, Atlanta, USA). Antimicrobial susceptibility proÞ le demonstrating multidrug resistance (MDR) [ Table 1 ] was determined by the broth dilution method and interpreted using the 2007 CLSI guidelines. [4] CDC considers MDR to S. pneumoniae when an isolate is non-susceptible to three of the following antibiotics: penicillin, erythromycin, trimethoprim-sulfamethoxazole, tetracycline, chloramphenicol, clindamycin, rifampin, and levoß oxacin. This study isolate belonged to serotype 23F and multilocus sequence type (MLST) ST1476, and is a single locus variant of ST81 from the internationally disseminated MDR clone Spain23F-1 [ Table 2 ], posted in http://www.sph.emory.edu/PMEN/index.html.
DISCUSSION
A well-known and widespread study conducted in Asia by ANSORP [1] [2] [3] (Asian Network for Surveillance of Resistant Pathogens) reported the highest prevalence of penicillin resistance in isolates from Vietnam (71.4%), followed 
*Blood isolate with meningeal syndrome and antigen positivity is considered as meningitis isolate for MIC interpretation and treatment as per the CLSI recommendation [1] 12.8% among carriage isolates; [2] 7.8% in 2000 -2001 among the clinical pathogens [3] ; and 1.48% in 1993-97 among clinical isolates. [5] Nevertheless, in 1999, [6] a 4.6% (n = 25) which included eight CSF isolates with intermediate resistant to penicillin (0.125-1.0 µg/ml) was reported. Likewise, point prevalence studies reported by other groups in India also had similar trends. This includes 7.3% (n = 11) isolates; [7] 15.4% (n = 2) [8] and 25% (n = 3); [9] 20% (n = 30) with 0.12 -1 µg/mL and 2 µg/mL of 26 and four respiratory isolates respectively. [10] However, in 2008, the Clinical Laboratory Standards Institute (CLSI) after re-evaluating with the more recent clinical data published new MIC penicillin break points for S. pneumoniae. [11] This latest recommendation for the Þ rst time is based on the clinical syndrome and route of penicillin administration. Further, this MIC break point tends to change the earlier Þ ndings of PIRSP, published in the literature up to early 2008, to a much lower percentage for non meningitis isolates [1] [2] [3] 5, [8] [9] [10] and higher percentage of complete penicillin resistance to meningitis isolates. [6, 7] However, this particular study isolate antimicrobial MIC break point interpretation remains valid as it conforms to CLSI 2008 recommendation also.
The emergence of PRSP may be due to extensive use of amoxicillin for the treatment of upper respiratory tract infections in the community. The appearance of resistant S. pneumoniae may be related to clonal penetration by resistant strains from neighboring countries. It is important to note that Sri Lanka reports much higher levels of penicillin resistance (> 90% in 2006-07-unpublished data; Southeast Asia Pneumococcal Network Alliance). In this setting Tamil Nadu may be a natural site where early penetration is likely to occur.
The emergence of resistant isolates can be effectively reduced by widespread pneumococcal vaccination. The available 23-valent pneumococcal polysaccharide vaccine for adults covers more than 80% and 7-valent pneumococcal conjugate vaccine for children covers around 50% of the serotypes identiÞ ed in an Invasive Bacterial Infection Surveillance (IBIS) study (unpublished data). Further, there is an urgent need to establish a molecular pneumococcal surveillance network in India to monitor the antimicrobial resistance, serotype distribution and MLST profile for preventive strategies.
This case report highlights the following:
The emergence of PRSP may predispose for an increased incidence of IPD especially in children with MDR proÞ le resulting in clinical failure.
This Þ nding signals the presence of the wellknown rapid disseminating Spanish 23F penicillinresistant clone in India
